NPPA fixes retail price of 9 combo drugs including Metformin, Paracetamol; Details

Published On 2019-07-04 09:10 GMT   |   Update On 2021-08-13 09:58 GMT

New Delhi: Through a recent notification, the government regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 9 drug formulations under the Drugs Prices Control Order (DPCO), 2013 exclusive of goods and services tax (GST).


The drugs whose price have been fixed by NPPA include Paracetamol Suspension, Metformin tablet, Clonazepam tablet in combination with other formulations. Some of the combinations are Mefenamic acid + Paracetamol tablet; Glimepiride + Metformin Tablet and others.


Notable drugmakers namely, Sun Pharmaceuticals Ltd (Sun Pharma), Lupin, Eris Lifesciences and others are responsible for manufacturing these widely used combinations drugs.


Combination of Gliclazide + Metformin Tablet is used in the treatment of type 2 diabetes mellitus. The drug is manufactured by various drugmakers including Lupin, Dr Reddy's Labs, Indoco Remedies, Mankind Pharma and others. The formulation is sold under popular brand names such as Glykind-M, Reclimet and so on.


While another widely used combination of Mefenamic acid + Paracetamol tablet sold under different brand names such as Meftagesic, Meftal Forte, Spasmonil Forte, is indicated for the short-term treatment of mild to moderate pain from various conditions. It is also used to decrease pain and blood loss from menstrual periods.


The details of the list of all 9 formulations read;






























































































Sl.

No.
Name of the Formulation /

Brand Name
StrengthUnitManufacturer & Marketing CompanyRetail Price

(Rs.)
(1)(2)(3)(4)(5)(6)
1.Mefenamic acid + Paracetamol tabletEach tablet contains:

Mefenamic acid IP 500mg, Paracetamol IP 325mg


1 Tablet
M/s Cris Pharma (India)

Ltd. / M/s Seagull Pharmaceuticals Pvt. Ltd.
2.76
2.Mefenamic acid + Paracetamol SuspensionEach 5ml Suspension contains: Mefenamic acid IP 100mg, Paracetamol IP 250mg

1 ML
M/s Cris Pharma (India) Ltd. / M/s Seagull Pharmaceuticals Pvt. Ltd.0.63
3.Glimepiride + Metformin TabletEach uncoated bilayered tablet contains: Glimepiride IP 2mg

Metformin Hydrochloride IP 1000mg (in prolonged release form)


1 Tablet
M/s Windlas Biotech Pvt. Ltd. / M/s Zuventus Healthcare Limited8.75
4.Glimepiride + Metformin tabletEach uncoated bilayered tablet contains: Glimepiride IP 1mg

Metformin Hydrochloride IP 500mg (in Sustain Release)


1 Tablet
M/s Swiss Garnier Biotech / M/s Zuventus Healthcare Limited5.46
5.Glimepiride + Metformin tabletEach uncoated bilayered tablet contains: Glimepiride IP 2mg

Metformin Hydrochloride IP 500mg (in Sustain Release)


1 Tablet
M/s Swiss Garnier Biotech / M/s Zuventus Healthcare Limited7.96
6.Escitalopram + Clonazepam tabletEach film coated tablet contains: Escitalopram Oxalate IP eq. to Escitalopram 5mg,

Clonazepam IP 0.5mg


1 Tablet


M/s Eris Lifesciences Ltd.
6.24
7.Telmisartan + Chlorthalidone tabletEach film coated tablet contains: Telmisartan IP 40mg, Chlorthalidone IP 12.5mg

1 Tablet
M/s Sun Pharma Laboratories Limited /

M/s Sun Pharmaceuticals Industries Limited
8.21
8.Glimepiride + Metformin TabletEach uncoated bilayered tablet contains: Glimepiride IP 1mg

Metformin Hydrochloride IP 1000mg (in prolonged release form)


1 Tablet
M/s Windlas Biotech Pvt. Ltd. / M/s Zuventus Healthcare Limited6.57
9.Gliclazide + Metformin TabletEach uncoated tablet contains: Gliclazide IP 80mg

Metformin Hydrochloride IP 500mg


1 Tablet
M/s Anphar Organics Pvt. Ltd. / M/s Lupin Limited6.65

The NPPA notice further adds;




  • The manufacturer of above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

  • The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.

  • The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

  • As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

  • The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

  • In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

  • Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.


Also Read: NPPA fixes retail price of 14 combo drugs including Aspirin, Paracetamol, Vitamin D3; Details

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News